A tailored course, built for your situation
Mastering EU GMP for Pharmaceutical Innovation Leaders
A structured path to confident, compliant decision-making in high-stakes drug development environments
$199 one-time
24-hour access provisioning
30-day money-back guarantee
Hand-built implementation playbook
12 modules. 12 chapters per module. 144 chapters total.
12 modules, each with 12 chapters (144 chapters total), text-based, plus downloadable templates and a hand-built implementation playbook delivered alongside course access.
Avoid undervaluing compliant innovation or overestimating superficial regulatory readiness
The situation this course is for
Many investment decisions hinge on incomplete or misinterpreted compliance signals, leading to delayed exits or costly remediation post-acquisition
Who this is for
Senior life sciences investor who evaluates technical and regulatory maturity across early-stage biotech portfolios
Who this is not for
Entry-level compliance staff, audit practitioners, or employees at companies solely focused on generic drug manufacturing
What you walk away with
- Discern true EU GMP readiness from checklist theatrics in under 45 minutes
- Apply a tiered assessment framework to prioritize ventures with faster regulatory pathways
- Integrate compliance depth scoring into early-stage due diligence templates
- Identify hidden remediation costs in target companies before term sheet issuance
- Build investor-grade narratives that align development timelines with inspection cycles
The 12 modules (with all 144 chapters)
Module 1. Understanding the Core Principles of EU GMP
Build a working mental model of EU GMP intent beyond checklists, focusing on data integrity, process validation, and quality culture as investment signals
12 chapters in this module
- What EU GMP really governs
- The shift from compliance to capability
- Key pillars of Annex 1 compliance
- Data integrity as a valuation signal
- Change control maturity indicators
- Quality risk management foundations
- Role of Qualified Person oversight
- Documentation expectations by phase
- Facility design red flags
- Vendor management depth
- Lifecycle approach to compliance
- Mapping GMP to development stage
Module 2. EU GMP and Early-Stage Biotech Assessment
Translate rigid manufacturing rules into flexible evaluation criteria for pre-commercial ventures with lab-scale or pilot operations
12 chapters in this module
- Assessing GMP intent in pre-clinical firms
- Tolerable vs critical gaps
- Scaling proof of concept to GMP readiness
- Interpreting batch records from CROs
- Analytical method validation depth
- Stability study sufficiency
- Facility flexibility under GMP
- GMP by design principles
- Regulatory strategy alignment
- GMP exposure in platform tech
- Due diligence red flags
- Scoring system for startups
Module 3. GMP Compliance in Outsourced Manufacturing
Evaluate CMO partnerships and supply chain depth with precision, identifying hidden liabilities in contract arrangements and oversight models
12 chapters in this module
- CMO selection criteria
- Audit rights in contracts
- Right to inspect clauses
- Change notification terms
- Data access guarantees
- Deviation management flow
- Batch release oversight
- Qualified Person delegation
- Cross-border implications
- Technology transfer risks
- Subcontractor oversight
- Performance benchmarking
Module 4. Data Integrity and ALCOA+ in Practice
Spot weak data governance in audit trails, electronic records, and lab workflows that could derail approval or trigger post-deal disputes
12 chapters in this module
- ALCOA+ principles overview
- Audit trail review methods
- Raw data definition
- Metadata completeness
- System validation scope
- Electronic signature validity
- Data lifecycle controls
- Hybrid record systems
- Cloud data residency
- Backup and recovery
- Access control depth
- Review frequency expectations
Module 5. Change Control and Deviation Management
Assess how organizations handle operational surprises, revealing cultural maturity and long-term sustainability beyond compliance theater
12 chapters in this module
- Change classification systems
- Impact assessment rigor
- Cross-functional review
- Approval authority levels
- Deviation root cause analysis
- CAPA effectiveness checks
- Trend reporting quality
- Recurrence rate benchmarks
- Minor vs major deviation
- Documentation timeliness
- Regulatory reporting triggers
- Ongoing stability review
Module 6. Quality Risk Management under ICH Q9
Apply formal risk tools to prioritize compliance investments and evaluate how portfolio companies justify control decisions
12 chapters in this module
- Risk assessment entry points
- Team composition norms
- Tools used in practice
- Documentation expectations
- Periodic review cycles
- Integration with change control
- Regulatory inspection use
- Risk tolerance definitions
- Failure mode identification
- Hazard analysis methods
- Risk acceptance criteria
- Audit trail for decisions
Module 7. Audits and Inspection Readiness
Predict inspection outcomes based on internal audit depth, preparation quality, and response patterns to previous findings
12 chapters in this module
- Internal audit frequency
- Audit scope breadth
- Finding severity distribution
- Response timeliness
- Corrective action depth
- Mock inspection utility
- Regulator interaction logs
- Observation trends
- 483 response quality
- Warning letter history
- Inspector feedback use
- Continuous readiness
Module 8. Regulatory Submissions and Compliance Evidence
Decode how quality data flows into regulatory dossiers and where gaps can compromise submission integrity
12 chapters in this module
- Module 3 quality structure
- Batch record inclusion
- Analytical method validation
- Stability data presentation
- Deviation summary format
- Change history summary
- Certificate of Analysis
- Specifications justification
- Reference standard use
- Comparability protocols
- Impurity profiling
- Manufacturing site summary
Module 9. GMP in Advanced Therapy Medicinal Products
Evaluate compliance depth in gene therapy, cell therapy, and RNA-based platforms where traditional rules evolve under real-world pressure
12 chapters in this module
- ATMP regulatory classification
- Starting material controls
- Patient-specific workflows
- Chain of identity
- Chain of custody
- Point-of-care manufacturing
- Viral vector safety
- Replication competent virus
- In-process testing
- Release specification debate
- Stability challenges
- Customization vs batch
Module 10. Vendor Oversight and Supply Chain Assurance
Map third-party risk across raw materials, components, and services with precision, identifying single points of failure in critical supply chains
12 chapters in this module
- Vendor qualification depth
- Criticality assessment
- Audit frequency benchmarks
- Raw material traceability
- Certificate of Analysis
- Dual sourcing strategy
- Packaging component risks
- Excipient documentation
- Single-use system validation
- Cold chain oversight
- Supplier quality agreements
- Supply disruption plans
Module 11. Building Investor-Grade Compliance Narratives
Develop compelling, evidence-based stories about compliance maturity that resonate with co-investors, acquirers, and regulatory bodies
12 chapters in this module
- Narrative timeline structure
- Risk to opportunity framing
- Evidence tiering
- Regulatory milestone alignment
- Inspection readiness claims
- CAPA progress reporting
- Quality culture signals
- Key performance indicators
- Benchmark comparisons
- Forward-looking statements
- Board communication style
- Investor Q&A preparation
Module 12. Future Trends in Pharmaceutical Quality
Anticipate upcoming shifts in inspection focus, digital compliance, and global harmonization that will impact portfolio company valuations
12 chapters in this module
- Real-time quality release
- Process analytical technology
- Continuous manufacturing
- AI in quality systems
- Digital batch records
- Blockchain for traceability
- MHRA innovation themes
- FDA emerging tech
- PIC/S convergence
- Environmental monitoring tech
- Remote inspection norms
- Sustainability integration
How this maps to your situation
- Pre-investment due diligence
- Post-acquisition integration planning
- Portfolio company escalation review
- Exit preparation and buyer questioning
Before vs. after
Before
Evaluating biotech ventures with incomplete compliance visibility, relying on surface-level documentation and vendor assurances
After
Confidently identifying audit-ready platforms with clear regulatory pathways, backed by structured assessment and investor-grade narratives
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 24 hours total, designed to be completed in 2-3 hour blocks across 6-8 weeks
If nothing changes
Continuing to rely on high-level compliance claims increases the likelihood of post-deal remediation costs, delayed approvals, and reputational exposure during regulatory scrutiny
How this compares to the alternatives
Unlike generic GMP training designed for operational staff, this course is tailored for investors who need to assess compliance depth as a strategic asset, not a cost center
Frequently asked
Is this course focused on operational execution or strategic evaluation?
Strategic evaluation. It's designed for investors and principals who assess maturity, not for lab or QA staff implementing daily controls.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Can I apply this to non-EU markets?
Yes. EU GMP sets the global benchmark, mastery here translates to stronger assessments in FDA, PIC/S, and emerging regulator environments.
$199 one-time. Approximately 24 hours total, designed to be completed in 2-3 hour blocks across 6-8 weeks.
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.
30-day money-back guarantee·
144 chapters·
Hand-built playbook included·
Account access within 24 hours